Search Results - "Bouwman, F H"

Trajectories of cognitive decline in different types of dementia by Smits, L L, van Harten, A C, Pijnenburg, Y A L, Koedam, E L G E, Bouwman, F H, Sistermans, N, Reuling, I E W, Prins, N D, Lemstra, A W, Scheltens, P, van der Flier, W M

“…To investigate trajectories of cognitive decline in patients with different types of dementia compared to controls in a longitudinal study. In 199 patients…”
Get more information

Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI by EWERS, M, BUERGER, K, WALLIN, A, DEBERNARDIS, J. F, KERKMAN, D. J, HEINDL, B, BLENNOW, K, HAMPEL, H, TEIPEL, S. J, SCHELTENS, P, SCHRÖDER, J, ZINKOWSKI, R. P, BOUWMAN, F. H, SCHÖNKNECHT, P, SCHOONENBOOM, N. S. M, ANDREASEN, N

“…The measurement of hyperphosphorylated tau (p-tau) in CSF has been proposed as a biomarker candidate for the prediction of Alzheimer disease (AD) in patients…”
Get full text

How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment - a bidding game experiment by van Maurik, I S, Bakker, E D, van Unnik, A A J M, Broulikova, H M, Zwan, M D, van de Giessen, E, Berkhof, J, Bouwman, F H, Bosmans, J E, van der Flier, W M

“…To estimate the perceived value of additional testing with amyloid-PET in Euros in healthy participants acting as analogue patients with mild cognitive…”
Get full text

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease by Schmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., Laczó, J., Molinuevo, J. L, O'Brien, J. T., Religa, D., Scheltens, P., Schott, J. M., Sorbi, S.

“…Background and purpose Previous studies have indicated clinical benefits of a combination of cholinesterase inhibitors (ChEI) and memantine over ChEI…”
Get full text

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease by VAN DER VLIES, A. E, VERWEY, N. A, BOUWMAN, F. H, BLANKENSTEIN, M. A, KLEIN, M, SCHELTENS, P, VAN DER FLIER, W. M

“…To investigate the relationship between CSF biomarkers and cognitive profiles in Alzheimer disease (AD). We included 177 patients with AD. Digit Span, Visual…”
Get full text

Longitudinal changes of CSF biomarkers in memory clinic patients by BOUWMAN, F. H, VAN DER FLIER, W. M, SCHOONENBOOM, N. S. M, VAN ELK, E. J, KOK, A, RIJMEN, F, BLANKENSTEIN, M. A, SCHELTENS, P

“…In Alzheimer disease (AD), longitudinal changes of beta-amyloid(1-42) (Abeta(1-42)), tau, and phosphorylated tau at threonine 181 (ptau-181) in CSF have been…”
Get full text

High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study by van Loenhoud, A C, de Boer, C, Wols, K, Pijnenburg, Y A, Lemstra, A W, Bouwman, F H, Prins, N D, Scheltens, P, Ossenkoppele, R, van der Flier, W M

“…Growing evidence suggests a role of occupation in the emergence and manifestation of dementia. Occupations are often defined by complexity level, although…”
Get full text

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment by Bouwman, F.H, Schoonenboom, S.N.M, van der Flier, W.M, van Elk, E.J, Kok, A, Barkhof, F, Blankenstein, M.A, Scheltens, Ph

“…Abstract Objective To study CSF biomarkers, beta-amyloid1-42 (Aβ1-42 ) and tau, and medial temporal lobe atrophy (MTA) on MRI in their ability to predict…”
Get full text

New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population by Bouwman, F H, Verwey, N A, Klein, M, Kok, A, Blankenstein, M A, Sluimer, J D, Barkhof, F, van der Flier, W M, Scheltens, P

“…In the newly proposed research criteria for Alzheimer's disease (AD), patients are defined as having memory dysfunction in addition to either hippocampal…”
Get more information

Variable progression of HIV-associated dementia by BOUWMAN, F. H, SKOLASKY, R. L, HES, D, SELNES, O. A, GLASS, J. D, NANCE-SPROSON, T. E, ROYAL, W, DAL PAN, G. J, MCARTHUR, J. C

“…A consecutive series of 71 patients diagnosed with HIV-associated dementia (HAD) (1984-1994) were studied to characterize the clinical course of HAD, and to…”
Get full text

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study by van Maurik, Ingrid S, Vos, Stephanie J, Bos, Isabelle, Bouwman, Femke H, Teunissen, Charlotte E, Scheltens, Philip, Barkhof, Frederik, Frolich, Lutz, Kornhuber, Johannes, Wiltfang, Jens, Maier, Wolfgang, Peters, Oliver, Rüther, Eckart, Nobili, Flavio, Frisoni, Giovanni B, Spiru, Luiza, Freund-Levi, Yvonne, Wallin, Asa K, Hampel, Harald, Soininen, Hilkka, Tsolaki, Magda, Verhey, Frans, Kłoszewska, Iwona, Mecocci, Patrizia, Vellas, Bruno, Lovestone, Simon, Galluzzi, Samantha, Herukka, Sanna-Kaisa, Santana, Isabel, Baldeiras, Ines, de Mendonça, Alexandre, Silva, Dina, Chetelat, Gael, Egret, Stephanie, Palmqvist, Sebastian, Hansson, Oskar, Visser, Pieter Jelle, Berkhof, Johannes, van der Flier, Wiesje M

“…Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for…”
Get full text

The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? by Duits, Flora H, Teunissen, Charlotte E, Bouwman, Femke H, Visser, Pieter-Jelle, Mattsson, Niklas, Zetterberg, Henrik, Blennow, Kaj, Hansson, Oskar, Minthon, Lennart, Andreasen, Niels, Marcusson, Jan, Wallin, Anders, Rikkert, Marcel Olde, Tsolaki, Magda, Parnetti, Lucilla, Herukka, Sanna-Kaisa, Hampel, Harald, De Leon, Mony J, Schröder, Johannes, Aarsland, Dag, Blankenstein, Marinus A, Scheltens, Philip, van der Flier, Wiesje M

“…Abstract Background We aimed to identify the most useful definition of the “cerebrospinal fluid Alzheimer profile,” based on amyloid-ß1-42 (Aβ42 ), total tau,…”
Get full text

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study by Vromen, Eleonora M, de Boer, Sterre C M, Teunissen, Charlotte E, Rozemuller, Annemieke, Sieben, Anne, Bjerke, Maria, Visser, Pieter Jelle, Bouwman, Femke H, Engelborghs, Sebastiaan, Tijms, Betty M

“…Abstract The biological definition of Alzheimer’s disease using CSF biomarkers requires abnormal levels of both amyloid (A) and tau (T). However, biomarkers…”
Get full text

Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review by van der Schaar, Jetske, Visser, Leonie N C, Bouwman, Femke H, Ket, Johannes C F, Scheltens, Philip, Bredenoord, Annelien L, van der Flier, Wiesje M

“…The NIA-AA research framework proposes a purely biological definition of Alzheimer's disease (AD). This implies that AD can be diagnosed based on biomarker…”
Get full text

Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study by Zwan, Marissa D, Rinne, Juha O, Hasselbalch, Steen G, Nordberg, Agneta, Lleó, Alberto, Herukka, Sanna-Kaisa, Soininen, Hilkka, Law, Ian, Bahl, Justyna M C, Carter, Stephen F, Fortea, Juan, Blesa, Rafael, Teunissen, Charlotte E, Bouwman, Femke H, van Berckel, Bart N M, Visser, Pieter J

“…To define CSF β-amyloid 1-42 (Aβ42) cutpoints to detect cortical amyloid deposition as assessed by 11C-Pittsburgh compound B ([11C]PiB)-PET and to compare…”
Get full text

Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease by van der Flier, Wiesje M, Staekenborg, Salka, Pijnenburg, Yolande A L, Gillissen, Freek, Romkes, Rolinka, Kok, Astrid, Bouwman, Femke H, Scheltens, Philip

“…We investigated differences in the prevalence and severity of 10 neuropsychiatric and behavioral symptoms according to apolipoprotein E (APOE) genotype and…”
Get more information

A survey study towards the opinions of clinicians, patients and care partners regarding computer tools in the memory clinic: sense or nonsense? by van Gils, Aniek M, Visser, Leonie Nc, Hendriksen, Heleen Ma, Muller, Majon, Bouwman, Femke H, van der Flier, Wiesje M, Rhodius-Meester, Hanneke Fm

“…Computer tools based on artificial intelligence could aid clinicians in memory clinics by supporting diagnostic decision-making and communicating diagnosis and…”
Get full text

Generative artificial intelligence in ophthalmology: multimodal retinal images for the diagnosis of Alzheimer's disease with convolutional neural networks by Slootweg, I. R, Thach, M, Curro-Tafili, K. R, Verbraak, F. D, Bouwman, F. H, Pijnenburg, Y. A. L, Boer, J. F, de Kwisthout, J. H. P, Bagheriye, L, González, P. J

“…Background/Aim. This study aims to predict Amyloid Positron Emission Tomography (AmyloidPET) status with multimodal retinal imaging and convolutional neural…”
Get full text

Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease by den Haan, Jurre, van de Kreeke, Jacoba A., Konijnenberg, Elles, ten Kate, Mara, den Braber, Anouk, Barkhof, Frederik, van Berckel, Bart N., Teunissen, Charlotte E., Scheltens, Philip, Visser, Pieter Jelle, Verbraak, Frank D., Bouwman, Femke H.

“…Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured…”
Get full text

Diabetic foot care within the context of rehabilitation: keeping people with diabetic neuropathy on their feet. A narrative review by van Deursen, Robert W.M., Bouwman, Everdien F.H.

“…A large percentage of patients with diabetes mellitus have neuropathy putting them at risk of developing severe foot problems. In diabetic foot care the…”
Get full text